Characterization of T and B cell epitopes of a simian retrovirus (SRV-2) envelope protein.

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Characterization of T and B cell epitopes of a simian retrovirus (SRV-2) envelope protein.

Symp Nonhum Primate Models AIDS. 1990 Nov 28-30;8:60 (abstract no. 44). Unique Identifier : AIDSLINE PRIM8/900044
Malley A; Werner L; Benjamini E; Leung CY; Torres J; Pangares N; Shiigi S; Axthelm M; Oregon Regional Primate Research Center, Beaverton OR

Abstract: Previously, we reported that the insoluble SRV-2 envelope peptide 92-106 represented the epitope involved in the formation of SRV-2 neutralizing antibodies. Soluble SRV-2 peptide 92-99 and peptide 100-106 were prepared and used to further define the epitope responsible for the induction of SRV-2 neutralizing antibody. SRV-2 peptide 100-106 (0.1 to 1.0 mu M) showed a dose independent inhibition of rhesus monkey neutralizing antibody, but the SRV-2 peptide 92-99 did not inhibit neutralization at any concentration tested (0.1 to 4 mu M). The T cell activating properties of SRV-2 peptides were studied by comparing SRV-2 virus and peptide induced proliferation of spleen cells from SRV-2 virus immunized mice. The optimal proliferation of T cells with the SRV-2 virus was obtained with 0.5 mu g of protein/well. T cell proliferation of SRV-2 virus primed spleen cells with unique SRV-2 envelope peptides 92-99 and 100-106 were optimal at 5 and 10 mu g/well, respectively. A peptide 233-239 common to both SRV-1 and SRV-2 also initiated T cell proliferation (optimal stimulation with 10 mu g/well). On the other hand, ovalbumin and a SIV envelope peptide 305-321 did not initiate proliferation of SRV-2 primed T cells. Specificity of the observed T cell proliferation was shown by the failure of the SRV-2 and SIV peptides to initiate proliferation of ovalbumin primed splenic T cells. The immune response of mice immunized with SRV-2 peptide 100-106 conjugated to keyhole limpet hemocyanin and the characterization of anti-peptide 100-106 monoclonal antibodies will be discussed.

Keywords: Animal Antibodies, Monoclonal/IMMUNOLOGY Antibodies, Viral/BIOSYNTHESIS B-Lymphocytes/DRUG EFFECTS/*MICROBIOLOGY Dose-Response Relationship, Drug Epitopes Lymphocyte Transformation/*DRUG EFFECTS Macaca mulatta Neutralization Tests Ovalbumin/PHARMACOLOGY Retroviruses Type D, Simian/DRUG EFFECTS/*IMMUNOLOGY Spleen/DRUG EFFECTS/MICROBIOLOGY T-Lymphocytes/DRUG EFFECTS/*MICROBIOLOGY Viral Envelope Proteins/ADMINISTRATION & DOSAGE/*PHARMACOLOGY ABSTRACT
910730
M9170950

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .